Welcome to
On Feet Nation
Posted by N1businessmaker on August 30, 2024 at 12:21pm 0 Comments 0 Likes
The global Erectile Dysfunction Drugs Market size is expected to reach USD 4.90 billion by 2030, expanding at a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.
Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.
Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda’s (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.
List of Key Players in Erectile Dysfunction Drugs Market
Related Press Release@ Erectile Dysfunction Drugs Market Report
Erectile Dysfunction Drugs Market Report Highlights
Report Attribute |
Details |
Market size value in 2024 |
USD 2.92 billion |
Revenue forecast in 2030 |
USD 4.90 billion |
Growth rate |
CAGR of 9.0% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Inquire@ https://www.grandviewresearch.com/inquiry/2643/ibb
Erectile Dysfunction Drugs Market Segmentation
Grand View Research has segmented the global erectile dysfunction drugs market based on product, route of administration, and region:
Erectile Dysfunction Drugs Product Outlook (Revenue, USD Million, 2018 - 2030)
Erectile Dysfunction Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Erectile Dysfunction Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
Explore Horizon, the world's most expansive market research database
© 2024 Created by PH the vintage.
Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation